Late Gadolinium Enhancement CMR for Detecting Myocardial Injury After Cancer Therapy

108 cancer patients and 60 healthy controls were examined by cardiac magnetic resonance imaging to assess cardiotoxicity. The presence of late gadolinium enhancement was found to be an important risk factor for left ventricular dysfunction in patients receiving cancer therapy. This dataset, authored by Xi Liu and licensed CC-BY-4.0, was last updated on 2026-05-01.

Use Cases

• Predicting left ventricular dysfunction based on the presence of late gadolinium enhancement.
• Analyzing correlations between myocardial strain parameters and cardiac biomarkers like N-terminal-pro B-type natriuretic peptide.
• Investigating the relationship between circumferential strain reduction and left ventricular ejection fraction.
• Comparing cardiac function metrics between cancer patients with and without myocardial injury and healthy controls.

Strengths

• Includes a control group of 60 healthy individuals for comparison.
• Dataset contains 108 cancer patient records with detailed cardiac imaging and biomarker data.
• Analysis includes multivariate linear regression revealing independent associations between key clinical factors.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Dataset size is only 29.0 KB, indicating a very limited scope of data.

Provenance

Source

figshare

Collection Method

Observational study using cardiac magnetic resonance imaging on cancer patients and healthy controls.

Freshness

Last updated 2026-05-01 04:16:37; freshness should be verified.